Global Hemato Oncology Testing Market
Global Hemato Oncology Testing Market

Hemato Oncology Testing Comprehensive Study by Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms, Others), Application (Assay Kits and Reagents, Services), Technology (PCR, HIS, NGS, Cytogenetics, Others), End-User (Hospitals, Academic & Research Institutes, Clinical Laboratories, Others) Players and Region - Global Market Outlook to 2026

Hemato Oncology Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 200 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hemato Oncology Testing Market?

Hemato oncology testing includes the analysis of blood disorders in the field of medicine such as iron deficiency anemia, hemophilia, sickle cell disease, leukemia, and lymphomas as well as cancers of other organs. Technological advancements with precise use of the information will make the entire hemato oncology testing reliable and effective. The part of hematological malignancies is helpful in the diagnosis and treatment of cancers of the bone marrow, blood and lymph nodes. Increasing cases of blood cancers, growing awareness among the population, and an increase in medical testing facilities are anticipated to propel the growth of the market during the forecast period.

The market study is being classified by Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms and Others), by Application (Assay Kits and Reagents and Services) and major geographies with country level break-up.

CORE Diagnostics (India), Tata Memorial Centre (India), Max Healthcare (India), Medanta The Medicity (India), Dr. Lal PathLabs (India), Narayana Hrudayalaya Ltd. (India), MedGenome (India), Oncquest.net (India), HealthCare Global Enterprises Ltd. (India) and The Mission Hospital (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (United States), Thermo Fisher Scientific, Inc. (United States), Adaptive Biotechnologies (United States), Invivoscribe, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), QIAGEN N.V. (Germany), Illumina, Inc. (United States), MolecularMD (Ireland), Asuragen, Inc. (United States) and ArcherDx, Inc. (United States).

Research Analyst at AMA predicts that India Players will contribute to the maximum growth of Global Hemato Oncology Testing market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Hemato Oncology Testing market by Type, Application and Region.

On the basis of geography, the market of Hemato Oncology Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Inclination of People towards an Early Detection of Serious Diseases, and Rise in Prevalence of Lymphoma & Myeloma Cancers
  • Growing Awareness about the Advanced Treatment Therapies among Population
  • Growing Focus on Personalized Medicine

Market Trend
  • Rise in the Availability of Advanced Molecular Techniques for the Diagnosis of Hemato Oncology

Restraints
  • Complex Regulatory Frameworks
  • Delay in the Approval of New Molecular Diagnostic Tests

Opportunities
  • Proliferation of Sequencing Techniques Such As NGS Due To the Increasing Cost of Development
  • Sequencing of the Human Genome Project in the Field Of Genomics

Challenges
  • Intellectual Property Rights Protection Issues


Market Leaders and some development strategies
In May 2018, Invivoscribe, Inc. has partnered with the American University of Beirut Medical Center (AUBMC) to create a new center of excellence facility in the Middle East.
In December 2019, Adaptive Biotechnologies collaborated with AbbVie for the use of Adaptive’s NGS based minimal residual disease testing in the drug trials of multiple myeloma.


Key Target Audience
Hemato Oncology Testing Service Providers, Hospitals & Clinics, Diagnostics Centers, Healthcare Professionals, End-Use Industries and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Leukemia
  • Lymphoma
  • Myeloproliferative Neoplasms
  • Others
By Application
  • Assay Kits and Reagents
  • Services
By Technology
  • PCR
  • HIS
  • NGS
  • Cytogenetics
  • Others

By End-User
  • Hospitals
  • Academic & Research Institutes
  • Clinical Laboratories
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Inclination of People towards an Early Detection of Serious Diseases, and Rise in Prevalence of Lymphoma & Myeloma Cancers
      • 3.2.2. Growing Awareness about the Advanced Treatment Therapies among Population
      • 3.2.3. Growing Focus on Personalized Medicine
    • 3.3. Market Challenges
      • 3.3.1. Intellectual Property Rights Protection Issues
    • 3.4. Market Trends
      • 3.4.1. Rise in the Availability of Advanced Molecular Techniques for the Diagnosis of Hemato Oncology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemato Oncology Testing, by Type, Application, Technology, End-User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hemato Oncology Testing (Value)
      • 5.2.1. Global Hemato Oncology Testing by: Type (Value)
        • 5.2.1.1. Leukemia
        • 5.2.1.2. Lymphoma
        • 5.2.1.3. Myeloproliferative Neoplasms
        • 5.2.1.4. Others
      • 5.2.2. Global Hemato Oncology Testing by: Application (Value)
        • 5.2.2.1. Assay Kits and Reagents
        • 5.2.2.2. Services
      • 5.2.3. Global Hemato Oncology Testing by: Technology (Value)
        • 5.2.3.1. PCR
        • 5.2.3.2. HIS
        • 5.2.3.3. NGS
        • 5.2.3.4. Cytogenetics
        • 5.2.3.5. Others
      • 5.2.4. Global Hemato Oncology Testing by: End-User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Academic & Research Institutes
        • 5.2.4.3. Clinical Laboratories
        • 5.2.4.4. Others
      • 5.2.5. Global Hemato Oncology Testing Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hemato Oncology Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. CORE Diagnostics (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Tata Memorial Centre (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Max Healthcare (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Medanta The Medicity (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Dr. Lal PathLabs (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Narayana Hrudayalaya Ltd. (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. MedGenome (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Oncquest.net (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. HealthCare Global Enterprises Ltd. (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. The Mission Hospital (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hemato Oncology Testing Sale, by Type, Application, Technology, End-User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Hemato Oncology Testing (Value)
      • 7.2.1. Global Hemato Oncology Testing by: Type (Value)
        • 7.2.1.1. Leukemia
        • 7.2.1.2. Lymphoma
        • 7.2.1.3. Myeloproliferative Neoplasms
        • 7.2.1.4. Others
      • 7.2.2. Global Hemato Oncology Testing by: Application (Value)
        • 7.2.2.1. Assay Kits and Reagents
        • 7.2.2.2. Services
      • 7.2.3. Global Hemato Oncology Testing by: Technology (Value)
        • 7.2.3.1. PCR
        • 7.2.3.2. HIS
        • 7.2.3.3. NGS
        • 7.2.3.4. Cytogenetics
        • 7.2.3.5. Others
      • 7.2.4. Global Hemato Oncology Testing by: End-User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Academic & Research Institutes
        • 7.2.4.3. Clinical Laboratories
        • 7.2.4.4. Others
      • 7.2.5. Global Hemato Oncology Testing Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemato Oncology Testing: by Type(USD Million)
  • Table 2. Hemato Oncology Testing Leukemia , by Region USD Million (2015-2020)
  • Table 3. Hemato Oncology Testing Lymphoma , by Region USD Million (2015-2020)
  • Table 4. Hemato Oncology Testing Myeloproliferative Neoplasms , by Region USD Million (2015-2020)
  • Table 5. Hemato Oncology Testing Others , by Region USD Million (2015-2020)
  • Table 6. Hemato Oncology Testing: by Application(USD Million)
  • Table 7. Hemato Oncology Testing Assay Kits and Reagents , by Region USD Million (2015-2020)
  • Table 8. Hemato Oncology Testing Services , by Region USD Million (2015-2020)
  • Table 9. Hemato Oncology Testing: by Technology(USD Million)
  • Table 10. Hemato Oncology Testing PCR , by Region USD Million (2015-2020)
  • Table 11. Hemato Oncology Testing HIS , by Region USD Million (2015-2020)
  • Table 12. Hemato Oncology Testing NGS , by Region USD Million (2015-2020)
  • Table 13. Hemato Oncology Testing Cytogenetics , by Region USD Million (2015-2020)
  • Table 14. Hemato Oncology Testing Others , by Region USD Million (2015-2020)
  • Table 15. Hemato Oncology Testing: by End-User(USD Million)
  • Table 16. Hemato Oncology Testing Hospitals , by Region USD Million (2015-2020)
  • Table 17. Hemato Oncology Testing Academic & Research Institutes , by Region USD Million (2015-2020)
  • Table 18. Hemato Oncology Testing Clinical Laboratories , by Region USD Million (2015-2020)
  • Table 19. Hemato Oncology Testing Others , by Region USD Million (2015-2020)
  • Table 20. South America Hemato Oncology Testing, by Country USD Million (2015-2020)
  • Table 21. South America Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 22. South America Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 23. South America Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 24. South America Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 25. Brazil Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 26. Brazil Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 27. Brazil Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 28. Brazil Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 29. Argentina Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 30. Argentina Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 31. Argentina Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 32. Argentina Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 33. Rest of South America Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 36. Rest of South America Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 37. Asia Pacific Hemato Oncology Testing, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 41. Asia Pacific Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 42. China Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 43. China Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 44. China Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 45. China Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 46. Japan Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 47. Japan Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 48. Japan Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 49. Japan Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 50. India Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 51. India Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 52. India Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 53. India Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 54. South Korea Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 55. South Korea Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 56. South Korea Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 57. South Korea Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 58. Taiwan Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 59. Taiwan Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 60. Taiwan Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 61. Taiwan Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 62. Australia Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 63. Australia Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 64. Australia Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 65. Australia Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 70. Europe Hemato Oncology Testing, by Country USD Million (2015-2020)
  • Table 71. Europe Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 72. Europe Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 73. Europe Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 74. Europe Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 75. Germany Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 76. Germany Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 77. Germany Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 78. Germany Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 79. France Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 80. France Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 81. France Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 82. France Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 83. Italy Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 84. Italy Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 85. Italy Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 86. Italy Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 87. United Kingdom Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 90. United Kingdom Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 91. Netherlands Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 92. Netherlands Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 93. Netherlands Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 94. Netherlands Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 95. Rest of Europe Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 98. Rest of Europe Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 99. MEA Hemato Oncology Testing, by Country USD Million (2015-2020)
  • Table 100. MEA Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 101. MEA Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 102. MEA Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 103. MEA Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 104. Middle East Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 105. Middle East Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 106. Middle East Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 107. Middle East Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 108. Africa Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 109. Africa Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 110. Africa Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 111. Africa Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 112. North America Hemato Oncology Testing, by Country USD Million (2015-2020)
  • Table 113. North America Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 114. North America Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 115. North America Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 116. North America Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 117. United States Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 118. United States Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 119. United States Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 120. United States Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 121. Canada Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 122. Canada Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 123. Canada Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 124. Canada Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 125. Mexico Hemato Oncology Testing, by Type USD Million (2015-2020)
  • Table 126. Mexico Hemato Oncology Testing, by Application USD Million (2015-2020)
  • Table 127. Mexico Hemato Oncology Testing, by Technology USD Million (2015-2020)
  • Table 128. Mexico Hemato Oncology Testing, by End-User USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Hemato Oncology Testing: by Type(USD Million)
  • Table 140. Hemato Oncology Testing Leukemia , by Region USD Million (2021-2026)
  • Table 141. Hemato Oncology Testing Lymphoma , by Region USD Million (2021-2026)
  • Table 142. Hemato Oncology Testing Myeloproliferative Neoplasms , by Region USD Million (2021-2026)
  • Table 143. Hemato Oncology Testing Others , by Region USD Million (2021-2026)
  • Table 144. Hemato Oncology Testing: by Application(USD Million)
  • Table 145. Hemato Oncology Testing Assay Kits and Reagents , by Region USD Million (2021-2026)
  • Table 146. Hemato Oncology Testing Services , by Region USD Million (2021-2026)
  • Table 147. Hemato Oncology Testing: by Technology(USD Million)
  • Table 148. Hemato Oncology Testing PCR , by Region USD Million (2021-2026)
  • Table 149. Hemato Oncology Testing HIS , by Region USD Million (2021-2026)
  • Table 150. Hemato Oncology Testing NGS , by Region USD Million (2021-2026)
  • Table 151. Hemato Oncology Testing Cytogenetics , by Region USD Million (2021-2026)
  • Table 152. Hemato Oncology Testing Others , by Region USD Million (2021-2026)
  • Table 153. Hemato Oncology Testing: by End-User(USD Million)
  • Table 154. Hemato Oncology Testing Hospitals , by Region USD Million (2021-2026)
  • Table 155. Hemato Oncology Testing Academic & Research Institutes , by Region USD Million (2021-2026)
  • Table 156. Hemato Oncology Testing Clinical Laboratories , by Region USD Million (2021-2026)
  • Table 157. Hemato Oncology Testing Others , by Region USD Million (2021-2026)
  • Table 158. South America Hemato Oncology Testing, by Country USD Million (2021-2026)
  • Table 159. South America Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 160. South America Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 161. South America Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 162. South America Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 163. Brazil Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 164. Brazil Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 165. Brazil Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 166. Brazil Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 167. Argentina Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 168. Argentina Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 169. Argentina Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 170. Argentina Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 171. Rest of South America Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 172. Rest of South America Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 173. Rest of South America Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 174. Rest of South America Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 175. Asia Pacific Hemato Oncology Testing, by Country USD Million (2021-2026)
  • Table 176. Asia Pacific Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 177. Asia Pacific Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 178. Asia Pacific Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 179. Asia Pacific Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 180. China Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 181. China Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 182. China Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 183. China Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 184. Japan Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 185. Japan Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 186. Japan Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 187. Japan Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 188. India Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 189. India Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 190. India Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 191. India Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 192. South Korea Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 193. South Korea Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 194. South Korea Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 195. South Korea Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 196. Taiwan Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 197. Taiwan Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 198. Taiwan Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 199. Taiwan Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 200. Australia Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 201. Australia Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 202. Australia Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 203. Australia Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 208. Europe Hemato Oncology Testing, by Country USD Million (2021-2026)
  • Table 209. Europe Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 210. Europe Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 211. Europe Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 212. Europe Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 213. Germany Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 214. Germany Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 215. Germany Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 216. Germany Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 217. France Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 218. France Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 219. France Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 220. France Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 221. Italy Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 222. Italy Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 223. Italy Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 224. Italy Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 225. United Kingdom Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 226. United Kingdom Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 227. United Kingdom Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 228. United Kingdom Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 229. Netherlands Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 230. Netherlands Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 231. Netherlands Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 232. Netherlands Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 233. Rest of Europe Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 234. Rest of Europe Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 235. Rest of Europe Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 236. Rest of Europe Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 237. MEA Hemato Oncology Testing, by Country USD Million (2021-2026)
  • Table 238. MEA Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 239. MEA Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 240. MEA Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 241. MEA Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 242. Middle East Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 243. Middle East Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 244. Middle East Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 245. Middle East Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 246. Africa Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 247. Africa Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 248. Africa Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 249. Africa Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 250. North America Hemato Oncology Testing, by Country USD Million (2021-2026)
  • Table 251. North America Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 252. North America Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 253. North America Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 254. North America Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 255. United States Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 256. United States Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 257. United States Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 258. United States Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 259. Canada Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 260. Canada Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 261. Canada Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 262. Canada Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 263. Mexico Hemato Oncology Testing, by Type USD Million (2021-2026)
  • Table 264. Mexico Hemato Oncology Testing, by Application USD Million (2021-2026)
  • Table 265. Mexico Hemato Oncology Testing, by Technology USD Million (2021-2026)
  • Table 266. Mexico Hemato Oncology Testing, by End-User USD Million (2021-2026)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemato Oncology Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Hemato Oncology Testing: by Application USD Million (2015-2020)
  • Figure 6. Global Hemato Oncology Testing: by Technology USD Million (2015-2020)
  • Figure 7. Global Hemato Oncology Testing: by End-User USD Million (2015-2020)
  • Figure 8. South America Hemato Oncology Testing Share (%), by Country
  • Figure 9. Asia Pacific Hemato Oncology Testing Share (%), by Country
  • Figure 10. Europe Hemato Oncology Testing Share (%), by Country
  • Figure 11. MEA Hemato Oncology Testing Share (%), by Country
  • Figure 12. North America Hemato Oncology Testing Share (%), by Country
  • Figure 13. Global Hemato Oncology Testing share by Players 2020 (%)
  • Figure 14. Global Hemato Oncology Testing share by Players (Top 3) 2020(%)
  • Figure 15. Global Hemato Oncology Testing share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. CORE Diagnostics (India) Revenue, Net Income and Gross profit
  • Figure 18. CORE Diagnostics (India) Revenue: by Geography 2020
  • Figure 19. Tata Memorial Centre (India) Revenue, Net Income and Gross profit
  • Figure 20. Tata Memorial Centre (India) Revenue: by Geography 2020
  • Figure 21. Max Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 22. Max Healthcare (India) Revenue: by Geography 2020
  • Figure 23. Medanta The Medicity (India) Revenue, Net Income and Gross profit
  • Figure 24. Medanta The Medicity (India) Revenue: by Geography 2020
  • Figure 25. Dr. Lal PathLabs (India) Revenue, Net Income and Gross profit
  • Figure 26. Dr. Lal PathLabs (India) Revenue: by Geography 2020
  • Figure 27. Narayana Hrudayalaya Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 28. Narayana Hrudayalaya Ltd. (India) Revenue: by Geography 2020
  • Figure 29. MedGenome (India) Revenue, Net Income and Gross profit
  • Figure 30. MedGenome (India) Revenue: by Geography 2020
  • Figure 31. Oncquest.net (India) Revenue, Net Income and Gross profit
  • Figure 32. Oncquest.net (India) Revenue: by Geography 2020
  • Figure 33. HealthCare Global Enterprises Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 34. HealthCare Global Enterprises Ltd. (India) Revenue: by Geography 2020
  • Figure 35. The Mission Hospital (India) Revenue, Net Income and Gross profit
  • Figure 36. The Mission Hospital (India) Revenue: by Geography 2020
  • Figure 37. Global Hemato Oncology Testing: by Type USD Million (2021-2026)
  • Figure 38. Global Hemato Oncology Testing: by Application USD Million (2021-2026)
  • Figure 39. Global Hemato Oncology Testing: by Technology USD Million (2021-2026)
  • Figure 40. Global Hemato Oncology Testing: by End-User USD Million (2021-2026)
  • Figure 41. South America Hemato Oncology Testing Share (%), by Country
  • Figure 42. Asia Pacific Hemato Oncology Testing Share (%), by Country
  • Figure 43. Europe Hemato Oncology Testing Share (%), by Country
  • Figure 44. MEA Hemato Oncology Testing Share (%), by Country
  • Figure 45. North America Hemato Oncology Testing Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • CORE Diagnostics (India)
  • Tata Memorial Centre (India)
  • Max Healthcare (India)
  • Medanta The Medicity (India)
  • Dr. Lal PathLabs (India)
  • Narayana Hrudayalaya Ltd. (India)
  • MedGenome (India)
  • Oncquest.net (India)
  • HealthCare Global Enterprises Ltd. (India)
  • The Mission Hospital (India)
Additional players considered in the study are as follows:
F. Hoffmann-La Roche Ltd. (Switzerland) , Abbott Laboratories (United States) , Thermo Fisher Scientific, Inc. (United States) , Adaptive Biotechnologies (United States) , Invivoscribe, Inc. (United States) , Bio-Rad Laboratories, Inc. (United States) , QIAGEN N.V. (Germany) , Illumina, Inc. (United States) , MolecularMD (Ireland) , Asuragen, Inc. (United States) , ArcherDx, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation